Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24789693 | 0.86 | POLRMT (0.38) | TMPRSS2PIK3CDPOLRMTCSNK2A2CSNK2A1 | |
| SCHEMBL10153929 | 0.86 | TMPRSS2 (0.44) | TMPRSS2PIK3CDPOLRMT | |
| SCHEMBL24791772 | 0.85 | POLRMT (0.37) | TMPRSS2PIK3CDPOLRMT | |
| SCHEMBL25918408 | 0.84 | TMPRSS2 (0.36) | TMPRSS2RIPK1 | |
| SCHEMBL26399124 | 0.84 | TMPRSS2 (0.35) | TMPRSS2PIK3CDRIPK1 | |
| SCHEMBL26328735 | 0.84 | TMPRSS2 (0.35) | TMPRSS2POLRMT | |
| SCHEMBL24313286 | 0.84 | TMPRSS2 (0.50) | TMPRSS2PIK3CDPOLRMTRIPK1 | |
| SCHEMBL23813355 | 0.84 | TMPRSS2 (0.37) | TMPRSS2RIPK1 | |
| SCHEMBL24074599 | 0.84 | POLRMT (0.49) | TMPRSS2POLRMT | |
| SCHEMBL23034569 | 0.83 | TMPRSS2 (0.36) | TMPRSS2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022142477-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PIK3CD 3488/4885POLRMT 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.